Standard Chem & Pharm Co Ltd

Standard Chem & Pharm Co Ltd maintains a strong liquidity position, with a current ratio of 2.53 and cash and equivalents of 1.03 billion TWD, indicating sufficient short-term liquidity to cover obligations. The company's price-to-book ratio of 1.77 and price-to-tangible-book ratio of 1.77 suggest that the market values the company's equity at a premium to its book value, while the price-to-earnings ratio of 11.69 indicates a relatively moderate valuation compared to earnings. In terms of profitability, the company's return on equity of 15.15% and return on assets of 7.86% outperform the typical thresholds for pharmaceutical firms, which often range between 10-15% for ROE and 5-10% for ROA. The operating margin of 19.39% (calculated from operating income of 1.36 billion TWD on revenue of 7.02 billion TWD) is also robust, suggesting efficient cost management and pricing power. The company's revenue is primarily concentrated in its domestic and overseas markets, with no disclosed segment or geographic breakdown in the provided data. However, the absence of segment-specific data limits the ability to assess the degree of geographic or product concentration risk. The company's exposure to international markets may introduce currency and regulatory risks, but these are not quantified in the available data. Looking at growth, the company's revenue of 7.02 billion TWD in the latest period suggests a stable performance, but without prior-year data, it is difficult to assess year-over-year growth. The company's capital expenditure of -506.91 million TWD indicates a reduction in investment, which may signal a focus on cost control or a shift in strategic priorities. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.15 suggests a conservative capital structure with limited leverage, reducing financial risk. The absence of dilution risk is supported by the fact that basic and diluted shares outstanding are equal, indicating no imminent share issuance. Recent events, including analyst estimates and financial filings, show that the company's last actual EPS was 5.18 TWD and revenue was 7.02 billion TWD, aligning with the financial snapshot. No recent filings or transcripts were provided that would indicate significant changes in the company's operations or strategy.